Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

Stock Summary

Top Correlated Resources

IFRX


In the News

07:30 29 Nov 2022 IFRX

InflaRx to Present at Upcoming Scientific and Investor Conferences

JENA, Germany, Sept. 09, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced its participation at several conferences.

01:33 29 Nov 2022 IFRX

Here's Why InflaRx N.V. (IFRX) is a Great Momentum Stock to Buy

Does InflaRx N.V. (IFRX) have what it takes to be a top stock pick for momentum investors?

01:33 29 Nov 2022 IFRX

InflaRx N.V. (IFRX) Upgraded to Buy: What Does It Mean for the Stock?

InflaRx N.V. (IFRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

11:30 29 Nov 2022 IFRX

Best Penny Stocks To Buy As Recession Begins? 5 Biotech Stocks To Watch

Biotech penny stocks to watch this week. The post Best Penny Stocks To Buy As Recession Begins?

03:12 29 Nov 2022 IFRX

Why Is InflaRx (IFRX) Stock Up 40% Today?

InflaRx (NASDAQ: IFRX ), a maker of anti-inflammatory therapeutics, is up 40% today after announcing it's pursuing emergency-use authorization from the U.S. Food and Drug Administration for its Covid-19 treatment. Its Vilobelimab is the treatment InflaRx is targeting for FDA approval.

12:09 29 Nov 2022 IFRX

InflaRx Provides Development Update For Vilobelimab In Skin Disorder, COVID-19

InflaRx N.V. (NASDAQ: IFRX) provided a development update for its monoclonal anti-C5a antibody, vilobelimab, in pyoderma gangrenosum (PG) and severe COVID-19.

07:30 29 Nov 2022 IFRX

InflaRx to Present at the H.C. Wainwright Global Investment Conference

JENA, Germany, May 17, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced that management will give a company presentation at the upcoming H.C. Wainwright Global Investment Conference.

01:33 29 Nov 2022 IFRX

InflaRx Shares Plunge After Disappointing Results On Vilobelimab In Critically Ill COVID-19 Patients

InflaRx N.V. (NASDAQ: IFRX) announced topline data from Phase 3 part of Phase 2/3 PANAMO study of vilobelimab in critically ill COVID-19 patients.

10:32 29 Nov 2022 IFRX

InflaRx N.V. (IFRX) Reports Q4 Loss, Misses Revenue Estimates

InflaRx N.V. (IFRX) delivered earnings and revenue surprises of 10.81% and 100%, respectively, for the quarter ended December 2021.

10:16 29 Nov 2022 IFRX

FDA Issues Corrected Advice To InflaRx's Vilobelimab Study In Skin Disease

InflaRx N.V. (NASDAQ: IFRX) has received a corrected advice letter from the FDA regarding its Phase 3 vilobelimab program for hidradenitis suppurativa (HS).

Financial details

Company Rating
Neutral
Market Cap
110.51M
Income
-34.13M
Revenue
0
Book val./share
2.25
Cash/share
2.25
Dividend
-
Dividend %
-
Employees
55
Optionable
No
Shortable
Yes
Earnings
09 Nov 2022
P/E
-1.96
Forward P/E
-
PEG
0.38
P/S
-
P/B
0.94
P/C
1.15
P/FCF
-2.33
Quick Ratio
9.58
Current Ratio
10.3
Debt / Equity
0.01
LT Debt / Equity
0.01
-
-
EPS (TTM)
-0.61
EPS next Y
-
EPS next Q
-
EPS this Y
-12.7%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-1900%
-
-
-
-
SMA20
-1.59%
SMA50
-6.06%
SMA100
72.22%
Inst Own
9.6%
Inst Trans
-3.04%
ROA
-31%
ROE
-34%
ROC
-0.37%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
44.2M
Shs Float
34.33M
-
-
-
-
Target Price
-
52W Range
0.776-5.4
52W High
-
52W Low
-
RSI
52.32
Rel Volume
1.32
Avg Volume
96.28K
Volume
127.26K
Perf Week
2.38%
Perf Month
7.95%
Perf Quarter
76.71%
Perf Half Y
62.26%
-
-
-
-
Beta
1.08691
-
-
Volatility
0.08%, 0.1%
Prev Close
3.2%
Price
2.58
Change
10.26%

Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2017-12-312018-12-312019-12-312020-12-31 2021-12-31
Revenue per share
00000
Net income per share
-2.58-1.19-2.05-1.26-1.1
Operating cash flow per share
-1.29-0.94-1.66-1.35-0.96
Free cash flow per share
-1.31-0.98-1.68-1.35-0.96
Cash per share
13.16.244.4432
Book value per share
12.696.034.122.882.53
Tangible book value per share
12.696.024.12.862.52
Share holders equity per share
12.696.034.122.882.53
Interest debt per share
0.2400.030.020.04
Market cap
181.82M699.65M73.16M122.85M124.56M
Enterprise value
58.53M644.26M40.88M97.44M99.74M
P/E ratio
-7.5-23.47-1.37-3.61-2.73
Price to sales ratio
00000
POCF ratio
-14.96-29.51-1.69-3.36-3.12
PFCF ratio
-14.78-28.54-1.67-3.35-3.12
P/B Ratio
1.524.620.681.581.18
PTB ratio
1.524.620.681.581.18
EV to sales
00000
Enterprise value over EBITDA
-2.99-14.99-0.72-3-2.13
EV to operating cash flow
-4.82-27.17-0.95-2.67-2.5
EV to free cash flow
-4.76-26.28-0.93-2.66-2.5
Earnings yield
-0.13-0.04-0.73-0.28-0.37
Free cash flow yield
-0.07-0.04-0.6-0.3-0.32
Debt to equity
00000.01
Debt to assets
0.040.050.120.120.16
Net debt to EBITDA
6.31.290.570.780.53
Current ratio
26.0120.398.468.545.1
Interest coverage
-8.7200-1.31K-1.92K
Income quality
0.50.80.811.070.88
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
0.010.030.0100
Capex to revenue
00000
Capex to depreciation
-2.1-4.63-0.9-0.13-0.06
Stock based compensation to revenue
00000
Graham number
27.1212.713.789.027.9
ROIC
-0.16-0.25-0.53-0.43-0.45
Return on tangible assets
-0.2-0.19-0.44-0.39-0.37
Graham Net
12.65.933.892.651.55
Working capital
119.21M150.4M104.93M76.19M76.92M
Tangible asset value
119.39M151.17M106.69M77.51M105.05M
Net current asset value
119.2M150.34M104.56M75.93M75.82M
Invested capital
000.010.010.01
Average receivables
769.75K001.42M1.35M
Average payables
6.36M7.46M10.34M8.26M8.42M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.2-0.2-0.5-0.44-0.43
Capex per share
-0.02-0.03-0.0200

Quarterly Fundamentals Overview

Last date of statement is 2022-09-30 for Q3

Metric History 2021-09-302021-12-312022-03-312022-06-30 2022-09-30
Revenue per share
00000
Net income per share
0-0.12-0.320.01-0.18
Operating cash flow per share
-0.23-0.11-0.29-0.28-0.07
Free cash flow per share
-0.23-0.11-0.29-0.28-0.07
Cash per share
2.130.792.042.272.25
Book value per share
2.6112.152.312.25
Tangible book value per share
2.612.152.312.25
Share holders equity per share
2.6112.152.312.25
Interest debt per share
0.030.010.030.040.03
Market cap
97.28M425.7M68.76M54.48M99.19M
Enterprise value
28.83M400.89M30.01M40.61M82.67M
P/E ratio
0-8.4-1.2329.27-3.13
Price to sales ratio
00000
POCF ratio
-9.77-36.32-5.35-4.36-31.32
PFCF ratio
-9.76-36.27-5.34-4.36-31.24
P/B Ratio
0.844.040.720.531
PTB ratio
0.844.040.720.531
EV to sales
00000
Enterprise value over EBITDA
0-31.23-2.06-43.07-9.56
EV to operating cash flow
-2.89-34.2-2.33-3.25-26.11
EV to free cash flow
-2.89-34.15-2.33-3.25-26.04
Earnings yield
0-0.03-0.20.01-0.08
Free cash flow yield
-0.1-0.03-0.19-0.23-0.03
Debt to equity
0.010.010.010.010.01
Debt to assets
0.110.160.170.110.11
Net debt to EBITDA
01.932.6614.721.91
Current ratio
7.745.15.479.9310.3
Interest coverage
0-1.53K-604.34-136.77-1.26K
Income quality
00.930.92-26.860.4
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
-0.02-0.1-0.05-0.01-0.06
Stock based compensation to revenue
00000
Graham number
01.653.920.743.01
ROIC
-0.11-0.12-0.15-0.01-0.09
Return on tangible assets
0-0.1-0.120-0.07
Graham Net
1.820.611.62.022.02
Working capital
87.3M76.92M84.75M100.84M98.18M
Tangible asset value
114.96M105.05M94.91M099.28M
Net current asset value
86.11M75.82M83.74M99.63M97.06M
Invested capital
0.010.010.010.020.01
Average receivables
1.22M1.4M1.34M1.52M1.55M
Average payables
9.71M8.24M8.71M7.91M7.68M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
0-0.12-0.150-0.08
Capex per share
00000

Frequently Asked Questions

What is InflaRx N.V. stock symbol ?

InflaRx N.V. is a DE stock , located in Jena of Thueringen and trading under the symbol IFRX

What is InflaRx N.V. stock quote today ?

InflaRx N.V. stock price is $2.58 today.

Is InflaRx N.V. stock public?

Yes, InflaRx N.V. is a publicly traded company.

Something similar